AstraZeneca plc (LON:AZN) had its target price raised by analysts at HSBC Holdings plc from GBX 4,100 ($53.90) to GBX 4,150 ($54.56) in a report released on Monday. The firm presently has a “reduce” rating on the biopharmaceutical company’s stock. HSBC Holdings plc’s target price points to a potential downside of 19.70% from the company’s previous close.
Several other research analysts also recently commented on AZN. UBS AG set a GBX 5,150 ($67.71) price objective on AstraZeneca plc and gave the stock a “neutral” rating in a report on Tuesday, June 27th. J P Morgan Chase & Co set a GBX 4,200 ($55.22) price objective on AstraZeneca plc and gave the stock a “neutral” rating in a report on Wednesday, August 9th. Barclays PLC restated an “overweight” rating and set a GBX 5,500 ($72.31) price objective on shares of AstraZeneca plc in a report on Monday, August 7th. Jefferies Group LLC reduced their price objective on AstraZeneca plc from GBX 4,900 ($64.42) to GBX 4,400 ($57.85) and set a “hold” rating on the stock in a report on Tuesday, August 1st. Finally, Investec upgraded AstraZeneca plc from a “hold” rating to a “buy” rating and reduced their price objective for the stock from GBX 5,000 ($65.74) to GBX 4,900 ($64.42) in a report on Wednesday, August 9th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of GBX 5,113.55 ($67.23).
Shares of AstraZeneca plc (AZN) opened at 5168.00 on Monday. The company’s 50 day moving average price is GBX 4,786.58 and its 200 day moving average price is GBX 4,901.67. The company’s market capitalization is GBX 65.43 billion. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.themarketsdaily.com/2017/10/11/astrazeneca-plc-azn-pt-raised-to-gbx-4150-at-hsbc-holdings-plc.html.
In other news, insider Nazneen Rahman bought 39 shares of AstraZeneca plc stock in a transaction that occurred on Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($57.45) per share, for a total transaction of £1,704.30 ($2,240.73).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.